$AEMD

Aethlon Medical (AEMD) reported a 12% narrower Q1 loss and progress in its Hemopurifier study, with shares up 17.5%. Quoin Pharmaceuticals (QNRX) surged 34% pre-market on positive QRX003 data and a $50M financing. Dogwood Therapeutics (DWTX) gained 12% as its Halneuron trial advances. Freenome (FRNM) rose 7% after FDA Breakthrough Device Designation for its lung cancer test.

Aethlon Medical (Nasdaq: AEMD) reported fiscal Q1 2027 results for the quarter ended June 30, 2026. It said it dosed the first participant in the third and final cohort of its Phase 1 oncology study in Australia and cited preliminary biomarker signals for its Hemopurifier. Cash was about $4.9M; it raised about $4.0M gross via a stock offering.

AETHLON MEDICAL INC (AEMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aethlon Medical Reports Q1 Fiscal 2027 Results and Progress on Hemopurifier® Program Conference Call Today at 4:30 p.m. ET SAN DIEGO, August 13, 2026 -- Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a clinical-stage medical therapeutic company, today

Aethlon Medical, Inc. (Nasdaq: AEMD) said it will release fiscal first-quarter results for the period ended June 30, 2026 on Aug. 13, 2026 at 4:15 p.m. ET, followed by a conference call at 4:30 p.m. ET. A replay will be available after the call through Sept. 13, 2026.

Aethlon Medical (Nasdaq: AEMD) reported that patients in the second cohort of its Australian Hemopurifier oncology feasibility study showed biological changes similar to cohort one. The company said biomarker shifts included reduced extracellular vesicles and improved immune-related ratios, with third-cohort enrollment underway before independent statistical analysis.

AETHLON MEDICAL INC (AEMD) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 6 aethlon_ex1001.htm FORM OF SECURITIES PURCHASE AGREEMENT Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of July 6, 2026, between Aethlon Medical, Inc., a Nevada corporation (the “ Company ”), and each purch

Aethlon Medical (AEMD) priced a $4.0 million follow-on at-the-market offering under Nasdaq rules. It will sell 5,633,009 common shares (or pre-funded warrants) with warrants for up to the same number of shares at $0.7101 per unit. Warrants exercise at $0.7101, exercisable after stockholder approval, expiring in five years. Net proceeds for general corporate uses; closing expected around July 7, 2026.

Aethlon Medical said its Hemopurifier investigational device study in Australia is over two-thirds complete, with the first two of three cohorts finished and enrollment/treatment ongoing in the third. The device is designed to remove cancer-associated extracellular vesicles and viruses from blood. The company expects final cohort completion in summer and data/regulatory submissions in Australia and the U.S. later in 2026, after receiving two FDA Breakthrough Device Designations.

Aethlon Medical (Nasdaq: AEMD) reported fiscal year results for the year ended March 31, 2026, and said its Australian oncology study has advanced to Cohort 3. The company reported the first Cohort 3 participant was treated at Royal North Shore Hospital. It also cited new U.S. and Europe patents and preclinical work in rheumatoid arthritis and chronic kidney disease. Cash was about $5.0M; operating expenses fell 21.9% to ~$7.3M.

Aethlon Medical reported fiscal year results for the year ended March 31, 2026, with about $5.0 million cash. It said its Australian oncology Hemopurifier study completed Cohort 2 and entered the final Cohort 3, treating the first participant at Royal North Shore Hospital. Operating expenses fell 21.9% to about $7.3 million; operating loss was about $7.3 million.